Design and stability study of an oral solution of amlodipine besylate for pediatric patients

详细信息    查看全文

• 作者：A.C. van der Vossen^a ; ^{a.vandervossen@erasmusmc.nl" class="auth_mail" title="E-mail the corresponding author} ; I. van der Velde^a ; O.S.N.M. Smeets^b ; D.J. Postma^b ; A. Vermes^a ; ^c ; B.C.P. Koch^a ; A.G. Vulto^a ; L.M. Hanff^a
• 关键词：Amlodipine besylate ; Pediatric formulation ; Hypertension ; Oral solution
• 刊名：European Journal of Pharmaceutical Sciences
• 出版年：2016
• 出版时间：20 September 2016
• 年：2016
• 卷：92
• 期：Complete
• 页码：220-223
• 全文大小：232 K

文摘

Amlodipine is an antihypertensive agent recommended for the management of hypertension in children and adolescents. The commercially available tablets of 5 and 10 mg do not provide the necessary flexibility in dosing needed for treating children. Our goal was to develop a pediatric oral solution of amlodipine, using a robust manufacturing process suitable for ex-tempora and larger scale production.

Methods

The parameters API and preservative content, related substances, appearance and pH were studied under four different storage conditions. Samples were analyzed up to 12 months. Microbiological quality was studied in an 18-week in-use test based on a two-times daily dosing schedule.

Results

The stability of the formulation was influenced by storage conditions and composition. A formulation containing amlodipine besylate, sucrose syrup and methyl paraben remained physically stable for 12 months at 4 °C with no loss of amlodipine content. Related substances increased during the study but remained below 0.5%. In-use stability was proven up to 18 weeks.

Discussion

Storage under refrigerated conditions was necessary to prevent precipitation and to obtain an acceptable shelf-life. In conclusion, we have developed and validated an amlodipine oral solution, suitable for the pediatric population. This liquid formulation is preferred over manipulated commercial dosage forms or non-standardized extemporaneously compounded formulations.